Literature DB >> 19124918

Prevalence of hepatitis B and C among HIV positive patients in Georgia and its associated risk factors.

N Badridze1, N Chkhartishvili, A Abutidze, L Gatserelia, L Sharvadze.   

Abstract

The aim of the study was to determine the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection among HIV positive patients, to identify most relevant risk factors of co-infection and develop preventive interventions. Study participants were voluntary individuals 18 years of age or older recruited from AIDS Center VCT unit in Tbilisi, Georgia. Eligibility criteria of participants were: HIV positive result confirmed by western blot; age; and voluntary participation. Total 175 patients undergo interview with specially designed questionnaires. Most of the participants were male (71.4%), age range of HIV positives varied from 20 to 77 years old. Prevalence of HCV among HIV positive patients is high. Almost half (48.57%) HIV positive patients are co-infected with HCV. Men were more likely than women co-infected with HCV (60.80% and 18% accordingly). Major risk factor of male co-infection was related to drug use, needle and injection equipment sharing. Prevalence of HCV among injecting drug users was (73.40%). Drug users had 3.25 times more risk (PR 3.25; 95%CI; CL--1.89-5.26; p<0.01) to be infected with HCV compare non IDUs. Prevalence of being infected with HBV (Anti-HBc) among HIV positives was 43.42% (76/175) and the prevalence of Chronic HBV (HBsAg positive) was 6.86% (12/175). Prevalence rate of HBsAg among IDUs was 8.51% and among non IDU participants 5.26%. Triple infection (HIV, Hepatitis C and chronic form of Hepatitis B--HBsAg) was among 9 patients (5.14%). Infections were associated with injection drug use (88.88%) and mostly were related to share of needles/syringes and other injecting medical equipment. Transmission of HBV and HCV by sexual contact was not observed among those 9 participants. High risk behavior among HIV positive participants mostly related to drug use and unprotected sex with non regular partners. Other risk factors for Hepatitis transmission were associated with invasive medical manipulations, blood transfusion, surgery, abortions and etc. None of cases of HIV, or Hepatitis (B, C) transmission through medical manipulations can be documentary proved based on those research data.

Entities:  

Mesh:

Year:  2008        PMID: 19124918

Source DB:  PubMed          Journal:  Georgian Med News        ISSN: 1512-0112


  5 in total

1.  Sero-prevalence and Correlates of Hepatitis B and C Co-infection Among HIV-infected Individuals in Two Regional Hospitals in Cameroon.

Authors:  Henry Namme Luma; Servais Albert Fiacre Bagnaka Eloumou; Domin Sone Majunda Ekaney; Fernando Kemta Lekpa; Olivier Donfack-Sontsa; Bertrand Hugo Mbatchou Ngahane; Yacouba Njankouo Mapoure
Journal:  Open AIDS J       Date:  2016-11-03

2.  Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia.

Authors:  Masoud Behzadifar; Hasan Abolghasem Gorji; Aziz Rezapour; Nicola Luigi Bragazzi
Journal:  J Virus Erad       Date:  2019-04-01

3.  Hepatitis C Virus Infection in HIV Positive Attendees of Shiraz Behavioral Diseases Consultation Center in Southern Iran.

Authors:  Mohammad Ali Davarpanah; Farnaz Khademolhosseini; Abdolreza Rajaeefard; Alireza Tavassoli; Seyed Kamalaldin Yazdanfar; Abbas Rezaianzadeh
Journal:  Indian J Community Med       Date:  2013-04

4.  Sero-prevalence of hepatitis B virus and hepatitis C virus among HIV patients in a suburban University Teaching Hospital in South-East Nigeria.

Authors:  Chiekulie Kevin Diwe; Emmanuel Chidiebere Okwara; Oguamanam Okezie Enwere; Jerome Emeka Azike; Nathan Chibuzo Nwaimo
Journal:  Pan Afr Med J       Date:  2013-09-10

Review 5.  HBV Prevention and Treatment in Countries of Central Asia and the Caucasus.

Authors:  Daulet Amerzhanov; Indira Suleimenova; Salima Davlidova; Zhamilya Nugmanova; Syed Ali
Journal:  Viruses       Date:  2020-09-30       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.